Thermo Fisher Scientific Inc. (NYSE:TMO) Holdings Decreased by Davis R M Inc.

Key Points

• Davis R M Inc. has reduced its stake in Thermo Fisher Scientific Inc. by 1.1%, now owning 129,695 shares, valued at $64.5 million.
• Thermo Fisher Scientific reported a quarterly earnings per share (EPS) of $5.36, exceeding estimates and showcasing a 2.9% increase in revenue year-over-year.
• The company announced a quarterly dividend of $0.43 per share to be paid on October 15, which represents a dividend yield of 0.36%.

Davis R M Inc. decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 129,695 shares of the medical research company's stock after selling 1,380 shares during the quarter. Thermo Fisher Scientific comprises 1.3% of Davis R M Inc.'s holdings, making the stock its 23rd biggest position. Davis R M Inc.'s holdings in Thermo Fisher Scientific were worth $64,536,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of TMO. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth $25,000. Ameriflex Group Inc. purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $30,000. IMA Advisory Services Inc. purchased a new position in Thermo Fisher Scientific during the first quarter valued at $35,000. Navigoe LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in Thermo Fisher Scientific during the first quarter valued at $37,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 1.1%

Shares of TMO stock traded down $4.94 during mid-day trading on Friday, reaching $462.74. 2,756,840 shares of the company were exchanged, compared to its average volume of 3,223,400. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market capitalization of $174.68 billion, a P/E ratio of 26.76, a P/E/G ratio of 2.50 and a beta of 0.74. The business's 50 day simple moving average is $420.88 and its 200 day simple moving average is $467.66.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the company earned $5.37 earnings per share. The business's quarterly revenue was up 2.9% compared to the same quarter last year. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on TMO shares. HSBC reaffirmed a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Argus reduced their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. UBS Group increased their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Finally, Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Six equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $593.00.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.